新型抗精神病药在儿重分裂症中的临床应用

目的比较新型抗精神病药newgenerationatypicaldrug，NAD）奥氮平、利培酮、奎硫平在儿童分裂症中的应用。方法共纳入使用奥氮平、利培酮及奎硫平的儿童分裂症患者66例，根据病历病情记录分别在治疗前及治疗第2、4、8周末采用临床疗效总评量表（CGI）评定临床疗效，用副反应量表（TESS）评定药物不良反应。结果利培酮组有效率为71．O％，奥氮平组有效率为85．7％，奎硫平组有效率为60．0％，总有效率为72．7％；利培酮组的副反应发生率为21．O％，奥氮平组的副反应发生率为33．0％，奎硫平组的副反应发生率为30．O％。结论NAD对儿童分裂症安全有效，NAD已较为广泛地应用于儿童精神分裂症。

The clinical use of NAD in the treatment of children schizophrenia

Objective To compare the use of new antipsychotic drugs (NAD) including Olanzapine, Risperidone and Qutipine in the treatment for children with schizophrenia. Methods 66 children patients were included in this study, according to the case disease condition history, we evaluated the efficacy and side effects with CGI and TESS before treatment, and at the 2nd,4th ,8th weeks after the treatment. Results The response rate of Risperidone, Olazapine and Qutipine are 71％, 85.7％, and 60％ respectively. The total response rate is 72.7％. The rates of side effects are 21％, 33％, 30％respectively. Conclusion It suggested that NAD is effective and safe in the treatment for children schizophrenia patients. NAD has been widely used in children schizophrenia outpatients.